Abstract
The leflunomide (CAS 75706-12-6) metabolite (LFM) analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13, DDE-28, CAS 244240-24-2), is a rationally designed inhibitor of the anti-apoptotic enzyme Bruton's tyrosine kinase (BTK). LFM-A13 is being developed as a novel dual-function anticancer drug with apoptosis-promoting and anti-thrombotic properties. LFM-A13 was prepared under current Good Manufacturing Practice (cGMP) conditions on the scale of kilograms.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Amides / chemical synthesis*
-
Antineoplastic Agents / chemical synthesis*
-
Chromatography, Gas
-
Chromatography, High Pressure Liquid
-
Crystallization
-
Drug Compounding / standards
-
Drug Contamination
-
Drug Industry / standards
-
Indicators and Reagents
-
Magnetic Resonance Spectroscopy
-
Mass Spectrometry
-
Metals, Heavy / analysis
-
Nitriles / chemical synthesis*
-
Particle Size
-
Spectrophotometry, Ultraviolet
-
Spectroscopy, Fourier Transform Infrared
-
Water / analysis
Substances
-
Amides
-
Antineoplastic Agents
-
Indicators and Reagents
-
LFM A13
-
Metals, Heavy
-
Nitriles
-
Water